US20060094689A1 - Production of fungal extracellular immune stimulating compounds - Google Patents

Production of fungal extracellular immune stimulating compounds Download PDF

Info

Publication number
US20060094689A1
US20060094689A1 US11/305,136 US30513605A US2006094689A1 US 20060094689 A1 US20060094689 A1 US 20060094689A1 US 30513605 A US30513605 A US 30513605A US 2006094689 A1 US2006094689 A1 US 2006094689A1
Authority
US
United States
Prior art keywords
immune stimulating
stimulating agent
fungal
lentinan
extracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/305,136
Inventor
Bjoern Kristiansen
David Waddell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/305,136 priority Critical patent/US20060094689A1/en
Publication of US20060094689A1 publication Critical patent/US20060094689A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0002Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention is directed to a method for producing an immune stimulant in liquid culture.
  • the invention is in one embodiment directed to culturing Lentinus edodes under particular conditions in a fermentation broth.
  • This application is a non-provisional claiming priority from Norwegian patent application No. NO 2001 4256 filed 3 Sep. 2001, which is hereby incorporated by reference in its entirety. All patent and non-patent references cited in that application, or in the present application, are also hereby incorporated by reference in their entirety.
  • Lentinus edodes One active ingredient of Lentinus edodes is termed lentinan, a polysaccharide based compound described as a beta-(1,3) glucan backbone With beta-(1,6) side chains.
  • Solid-state reactors are routinely used for culturing fungi such as Lentinus edodes . This is a technology which is used for many purposes such as composting, production of biological products such as enzymes, soy sauce, acetic acid, and the like.
  • Lentinus edodes can be cultivated on a suitable solid matrix provided by stems of tree or chips of wood to which is often added chemical compounds supporting the growth of mycelium and development of the fruiting bodies, where most of the lentinan is localised.
  • the fruiting bodies are harvested, either by hand or mechanically, and are subsequently dried and ground to a powder which can be used as it is, or used in tablets, or sent for further processing such as extraction of lentinan.
  • the methods used for culturing fungi such as Lentinus edodes , harvesting and subsequently drying the fruiting bodies, and optionally extraction of lentinan, are well known for the skilled person.
  • the cultivation time can be from four to ten weeks with few possibilities for controlling the process. This results in a fungal growth, and in turn, in an amount of lentinan produced which is not the same for each batch carried out. Also, extraction of lentinan from the fungal material is time consuming and process intensive.
  • Kim et al. (2001, Biotechnology Letters, 23, 513-517) describes extracellular polysaccharides produced by Phellinus lintus in submerged culture; Kim et al. (2002: Letters in Applied Microbiology, 34, 56-61) describes mycelial growth and exobiopolymer production by submerged culture of various edible mushrooms. There is no data available to indicate that any of these extracellular polymers are immune stimulating.
  • the invention in a first aspect, relates to a method for cultivating a fungal mycelium, preferably a fungus from the class of basidiomycetes, such as a fungus of the genus Lentinus , such as Lentinus edodes , in a liquid medium of sterile water to which nutrient compounds are added in predetermined concentrations.
  • the liquid medium supports fungal growth and stimulates the production of extracellular compounds, such as immune stimulating agents, such as lentinan produced by fungal mycelium of the genus Lentinus , such as e.g. Lentinus edodes.
  • fungal mycelium any fungal biomass, which can be grown in submerged culture according to the invention.
  • the fungal biomass may be in the form of single hyphae, spores, aggregates of mycelium, and partly differentiated mycelium.
  • Lentinan refers to the polysaccharide, which can be isolated from Lentinus edodes (Berk.) Sing.
  • the primary structure is a ⁇ 1,3-D-glucan having 2 ⁇ -1,6-glucopyranoside branchings for every 5 ⁇ -1,3 linear linkages.
  • the molecular weight may vary from 400,000 to 800,000 (Merck Index 12 th Edition, 1996, Monograph No 5462).
  • the cultivation of the fungal mycelium results in the production of one or more extracellular agents, such as e.g. immune stimulating agents, in the form of e.g. a polysaccharide, such as e.g. a beta-glucan, including lentinan isolatable from Lentinus edodes , a polypeptide, a glycosylated polypeptide or a proteinacious polysaccharide compound, a proteoglucan, such as e.g.
  • a polysaccharide such as e.g. a beta-glucan
  • lentinan isolatable from Lentinus edodes a polypeptide, a glycosylated polypeptide or a proteinacious polysaccharide compound, a proteoglucan, such as e.g.
  • a polypeptide associated alpha-glucan or a polypeptide associated alpha-mannan including KS-2 isolatable from Lentinus edodes , a lipid, or a secondary metabolite, which can be isolated and/or purified, and optionally fractionated, from the extracellular fraction of the fermentation broth of a bioreactor following cultivation of the basidiomycete fungal mycelium in question.
  • the extracellular fraction of the liquid fermentation medium is also termed the supernatant and this fraction can be separated from the fungal mycelium by e.g. centrifugation or filtration, or indeed by any other means available for obtaining a liquid fraction essentially without any fungal mycelium present therein.
  • the term “essentially without any fungal mycelium present therein” shall denote that the concentration of fungal mycelium, including fractions thereof, has been reduced at least by a factor of 10 3 , such as reduced by a factor of at least 10 4 , for example a factor of at least 10 5 , such as reduced by a factor of at least 10 6 .
  • fungal extracellular agents such as immune stimulating agents according to the present invention are surprisingly more potent than fungal associated agents, i.e. agents being either fungal intracellular agents, or agents which are removed from a liquid fermentation broth along with the removal of the fungal mycelium and fractions thereof by filtration, precipitation, or otherwise.
  • the invention relates to an immune stimulating agent obtainable from the extracellular part of the liquid growth medium according to the method of producing said immune stimulating agent.
  • This immune stimulating agent has surprisingly turned out to have a higher immunostimulating activity than the corresponding extract obtainable from the mycelium of the fungus, although the mycelium is known as the primary source of e.g. lentinan.
  • this extract is obtainable by removal of mycelium, removal of water from the medium, one or more rounds of precipitation with alcohol and washing with acid and/or base.
  • composition comprising the immune stimulating agent obtainable as described above and a physiologically acceptable carrier.
  • a pharmaceutical composition comprising the immune stimulating agent according to the invention and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition may in particular be used for treatment or prophylaxis in connection with an immune compromised condition.
  • Fungi belonging to the genus of Lentinus represent one example of fungi according to the present invention.
  • the fungus is selected from the group of fungi consisting of Auricularia auricula - judae, Coriolus versicolor, Grifola frondosa, Flammulina velutipes, Schizophyllum commune, Sclerotinia scleroticum, Trametes versicolor, Tremella fuciformis, Agaricus blazei, Cordyceps sinensis, Ganoderma lucidum, Hericium erinaceus, lonotus obliquus, Pleurotus ostreatus , and Polyperus umbellatus.
  • liquid-state cultivation of Lentinus mycelium , or fractions thereof is used.
  • this involves dissolving in water the nutrient compounds a microbial organism such as fungal mycelium, or fractions thereof, require for growth, transferring the solution to a bioreactor and inoculating the bioreactor with cells or spores of the microbial organism such as a fungal mycelium, or fractions thereof, to be cultivated. This is done under sterile conditions and with control of the environment in order to give the microbial organism a suitable chemical and physical environment.
  • the technology related to “liquid-state” cultivation of microbial organisms is well known for the skilled person.
  • liquid-state as compared to “semi-solid-state” or “solid-state” cultivation is that “liquid-state” proceeds more rapidly, is more effective with respect to conversion of the raw materials to products, and most importantly, it offers greater possibilities for controlling the growth conditions and thereby the reproducibility and the predictability of the process.
  • the various “liquid-state” processes are the microbial organisms which are used and the cultivation conditions.
  • the microbial organism will be Lentinus edodes which is cultivated under the conditions described below.
  • the medium with the fungal biomass is preferably agitated to reduce the occurrence of gradients and to ensure oxygen availability to the submerged cells.
  • oxygen may be supplied to the liquid medium and the level of dissolved oxygen may be controlled by known methods.
  • a method for production of lentinan characterised by cultivating mycelium from Lentinus edodes in a liquid growth medium comprising one or more typical ingredients required for growth of microbial organisms such as malt extract, yeast extract, peptone, glucose, sucrose, salts providing phosphate, magnesium and potassium, corn-steep liquor and vitamins such as thiamine. More preferably, the medium comprises malt extract, yeast extract, peptone and glucose for mycelium growth and production of lentinan.
  • Lentinus edodes mycelium from agar plates containing malt extract, yeast extract, peptone and glucose can be used. Lentinus edodes can initially be cultivated on agar plates comprising the above nutrient compounds supporting the growth of the fungus.
  • the plates are inoculated with mycelium from Lentinus edodes and incubated at least until a visible growth is evident on the plates, this can take from about 7 days to about 24 days or from about 10 to 30 days, typically 14 days or up to 20 days, at a temperature in the range of from 18 to 32° C., preferably in the area of from 22 to 31° C., such as a temperature of about 23° C., for example 24° C., such as 25° C., for example 26° C., such as 27° C., for example 28° C., such as 29° C., for example 30° C.
  • the temperature may also be from 18 to 37° C., preferably from 23 to 32° C. such as about 28° C.
  • inoculation of the growth medium can be carried out by using Lentinus edodes mycelium from a fermentation broth in e.g. a shake flask medium comprising nutrient compounds supporting cell growth.
  • Shake flasks for cultivating Lentinus edodes can initially be inoculated with the mycelium which is cultivated on agar plates. The mycelium is scraped off the plates and transferred aseptically to shake flasks containing sterile water comprising dissolved nutrient compounds and nutrient salts supporting the growth of the fungal mycelium.
  • a typical growth medium contains glucose, peptone, yeast extract and malt extract. The amount of inoculation material which gives the highest production of extracellular lentinan can be selected following initial experiments.
  • the shake flasks can be incubated by shaking for 6 to 21 days, preferably from 7 to 18 days, more preferably from 8 to 14 days at a temperature in the range of from 18 to 32° C., preferably in the area of from 22 to 31° C., such as a temperature of about 23° C., for example 24° C., such as 25° C., for example 26° C., such as 27° C., for example 28° C., such as 29° C., for example 30° C.
  • the shake flasks may also be incubated from 8-25 days, more preferably from 10-20 days, more preferably from 12-18 days.
  • the temperature may also be from 18 to 37° C., preferably from 23 to 32° C. such as about 28° C.
  • the content of the shake flasks can be used for inoculating a bioreactor.
  • the reactor comprises a sterile solution of nutrient compounds and nutrient salts in water for mono-culture cultivation of basidiomycete fungal mycelium, or fractions thereof, such as Lentinus fungal mycelium, such as Lentinus edodes.
  • the bioreactor fermentation period is typically in the range of from 50 hours to 300 hours, preferably in the range of from 80 hours to 270 hours, and the temperature is kept constant in the range of 18 to 32° C., preferably in the area of from 22 to 31° C., such as a temperature of about 23° C., for example 24° C., such as 25° C., for example 26° C., such as 27° C., for example 28° C., such as 29° C., for example 30° C.
  • the temperature may also be from 18 to 37° C., preferably from 23 to 32° C. such as about 28° C.
  • the reactor is fitted with an inlet for supplying air to the fermentation broth, and the fermentation broth is preferably kept under continuous agitation either as a result of the addition of air, or by means of a mixer device suitable for providing a good mixing of the content of the reactor.
  • the pH of the growth medium is adjusted to from about 3 to about 7, such as a pH of from about 4.5 to about 6.5, for example a pH of about 6, before the growth medium is inoculated with fungal mycelium, or fractions thereof, such as L. edodes mycelium.
  • pH may be dropped naturally during the course of the fermentation, or controlled at a particular value in the range pH 3 to 7, using addition of suitable pH-control agents, such as acid and base.
  • the temperature of the growth medium is preferably in the range of from 18 to 32° C., preferably in the area of from 22 to 31° C., such as a temperature of about 23° C., for example 24° C., such as 25° C., for example 26° C., such as 27° C., for example 28° C., such as 29° C., for example 30° C.
  • the temperature may also be from 18 to 37° C., preferably from 23 to 32° C. such as about 28° C.
  • Samples can be obtained from the bioreactor and analysed for biomass, metabolic products and nutrient compounds, the determinations of which can assist the operator of the bioreactor in the running of the fermentation process.
  • Typical analyses routinely carried out are determination of biomass, residual sugar concentration and extracellular agent concentration, such as lentinan concentration in the case of Lentinus including Lentinus edodes .
  • a person skilled in the art knows the methods for analysis which can be employed in this respect.
  • extracellular lentinan may be removed from the liquid growth medium by precipitation with e.g. alcohol, or by other means which result in the isolation and/or purification of microbial polysaccharides. It is an important aspect of the present invention that such isolation from the growth medium is performed with gentle methods and is generally carried out at temperatures around room temperature. Therefore the extracted compounds are not degraded or converted as may often be the case when using harsh extraction conditions for extracting compounds from the mycelium or from the fruiting bodies of Lentinus edodes.
  • an immune stimulating agent preferably a polysaccharide or a glycosylated polypeptide, obtained from the cultivation of basidiomycete fungal mycelium such as Lentinus mycelium according to the method of the invention.
  • an extracellular agent such as lentinan in a method for stimulating the immune system of an individual in need of such stimulation.
  • the lentinan is administered e.g. orally or subcutaneously to the individual in a pharmaceutically effective amount capable of stimulating the immune system of the individual.
  • the stimulation of the immune system can be demonstrated by e.g. increased antibody production, by activation of helper T-cells, or by increased production of interleukins such as Interleukin 1 and Interleukin 2.
  • an extracellular agent such as lentinan in the manufacture of a medicament for treating an immune compromised condition in an individual in need of such treatment.
  • An immune compromised condition in an individual is demonstrated e.g. by an insufficient amount of antibodies, or a decreased antibody production, by an insufficient amount of helper T-cells, or a decreased production of helper T-cells in the individual, or by an insufficient amount of interleukins such as Interleukin 1 and Interleukin 2, or a decreased production of interleukins such as Interleukin 1 and Interleukin 2 in the individual.
  • “Insufficient amount” and “decreased production” as used herein above shall denote such amounts and productions which a medical expert considers as being below a predetermined level or value normally associated with a healthy individual. The amount and/or production will generally depend on factors such as age, general physical condition, and the like. For this reason a predetermined level or value shall be determined oh an individual basis by a medical expert.
  • One indication of an immune compromised condition in an individual is a gradually decreasing number of antibodies, a gradually decreasing number of CD4 (positive) cells, or a gradually decreasing number of T-helper cells per unit (blood) sample volume measured over time, such as days, weeks, months or years.
  • extracellular immunostimulants includes, but is not limited to, ⁇ -(1,3), ⁇ -(1,6) D-glucans, schizophyllan, grifolan, coriolan and Coriolus versicolor glycosylated polypeptides such as PSK and PSP, polypeptides associated with alpha-mannan such as KS-2 isolatable from Lentinus edodes , and reishi isolatable from Ganoderma lucidum .
  • Table 1 herein below for a further detailed description of the structure and composition of the above extracellular immunostimulants.
  • Preferred immunostimulating agents produced by fungal mycelium of the invention are polysaccharides such as polysaccharides comprising a ⁇ -D-glucan backbone (i.e. linear polymers of D-glucose with other monosaccharides), or ⁇ -D-glucans linked to proteins (so-called polysaccharide-peptides, or “proteoglucans”).
  • the preferred polysaccharides are homopolymers.
  • the basic ⁇ -D-glucan is a repeating structure with its D-glucose molecule joined by linear chains by ⁇ -bonds from the carbon 1 of one saccharide ring to the carbon 3 of the next ( ⁇ -1,3), from carbon 1 to carbon 4 ( ⁇ -1,4), or from carbon 1 to carbon 6 ( ⁇ -1,6).
  • the best know immune stimulating compound produced by Lentinus edodes is lentinan. This is ⁇ -(1,3) D-glucan with ⁇ -(1,6) side chains. The chain length varies with the typical product having a molecular weight in the range 400,000-1,000,000 g/mol. Further preferred polysaccharides are listed in Table 1.
  • an extracellular agent such as e.g. lentinan
  • 12 weeks old Sprague Dawley rats receive 1 mg of test compound which have been extracted from the fermentation broth in 0.5 ml 0.09 saline (i.p.) 2 days before the immunisation.
  • Control animals receive 1 mg casein.
  • the animals are immunised with BSA (0.5 mg) in 0.25 “Freunds Complete Adjuvant” and blood samples are obtained after 11 days for measurement of the antibody response.
  • the specific anti-BSA antibody concentration is determined against an absolute standard of antibody BSA by means of “sandwich” ELISA.
  • a typical result of the immuno-stimulating activity of intracellular and extracellular lentinan is shown in Table 7a and 7b.
  • Further additional preferred embodiments of the present invention relate to extracellular agents, other than immunostimulating agents, produced by a number of fungi, as well as to methods for producing said agents and methods for using said agents.
  • the fungi of particular interest to the present invention include Lentinus edodes, Ganoderma lucidum, Auricularia auricula - judae, Coriolus versicolor, Grifola frondosa, Flammulina velutipes, Schizophyllum commune, Sclerotinia scleroticum, Trametes versicolor, Tremella fuciformis, Agaricus blazei, Cordyceps sinensis, Ganoderma lucidum, Hericium erinaceus, lonotus obliquus, Pleurotus ostreatus , and Polyperus umbellatus.
  • the above fungal mycelium can be cultivated in mono-culture in a bio-reactor under suitable growth conditions allowing growth and propagation of the fungal mycelium in question.
  • the growth conditions cited herein for Lentinus edodes can also be used for the above fungal mycelium.
  • extracellular fungal immune stimulating agents such as extracellular proteinacious compounds, including glycosylated polypolypeptides, such as the alpha-mannan polypeptide KS-2, and extracellular polysaccharides, such as extracellular lentinan produced by Lentinus edodes
  • extracellular fungal immune stimulating agents such as extracellular proteinacious compounds, including glycosylated polypolypeptides, such as the alpha-mannan polypeptide KS-2, and extracellular polysaccharides, such as extracellular lentinan produced by Lentinus edodes
  • the fungal microbial organisms of the invention such as e.g.
  • the polysaccharide chains are true glucans, mainly 1,4; 1,2 and 1,3 glucose linkages Lentinus edodes KS-2 Polypeptide associated ⁇ -mannan Lentinus edodes lentinan ⁇ -(1,3), ⁇ -(1,6) D glucan Ganoderma lucidum reishi
  • the basic structure of the major bioactive Ganoderma glucans ⁇ - (1,3), ⁇ -(1,6) D glucan is ⁇ -(1,3)D- glucopyronan with 1-5 units of ⁇ - (1,6) monoglucosyl side chains
  • the effects associated with the above extracellular agents produced by the fungi of the invention are e.g. analgesic effects, anti-allergic activity, bronchitis-preventative effects, anti-inflammatory activity, anti-bacterial properties (against Staphylococci, Streptococci and Bacillum pneumoniae ), antioxidant effects, antitumor activity, blood pressure lowering effects, bone marrow formation enhancing effects, cardiotonic activity (i.e.
  • the invention relates to a method of treatment of an individual diagnosed with an immune compromised condition, said method comprising the steps of administering to said individual the composition according to the invention or the pharmaceutical composition according to the invention in an amount effective in treating said immune compromised condition.
  • the administered amount may in be an amount effective in prophylactically treating said immune compromised condition.
  • a method of treatment of an individual diagnosed with or at risk of contracting acquired immunodeficiency syndrome comprising the steps of administering to said individual the composition according to the invention or the pharmaceutical composition according to the invention in an amount effective in treating or prophylactically treating said syndrome.
  • the immune compromised condition may be selected from the group consisting of an infectious disease, a parasitic disease, haemophilus meningitis, pneumococcal meningitis, streptococcal meningitis, staphylococcal meningitis, meningitis due to other organisms, encephalitis, viral pneumonia, pneumococcal pneumonia, other bacterial pneumonia, pneumonia due to other specified organisms except bacteria, bronchopneumonia, organism unspecific pneumonia, influenza, unspecified diarrhea, hepatitis unspecified, acute and subacute necrosis of the liver, chronic hepatitis, and abscess of liver.
  • the immune compromised condition may be an infectious or parasitic disease caused by, or selected from, cholera, salmonella , shigellosis, Escherichia coli , intestinal infection due to other specified bacteria, Clostridium difficile , viral gastroenteritis, infectious colitis, enteritis and gastroenteritis, infectious diarrhea, tuberculosis, listeriosis, pasteurellosis, mycobacterium , diphtheria, pertussis, meningococcus, streptococcus septicaemia, staphylococcus septicaemia, pneumococcal septicaemia, septicaemia due to anaerobes, septicaemia due to other gram-negative organisms, actinomycotic infection, gas gangrene, toxic shock syndrome, necrotizing faciitis, Friedlander's bacillus, haemophilus influenzae, pseudomonas , AIDS/HIV infections, acute poliomyelitis, Creutzfeldt-Jaco
  • the individual may be a mammal including a human being.
  • the pharmaceutical composition according to the invention may also be used in the manufacture of a medicament for treatment of an immune compromised condition of an individual in need of such treatment.
  • the immune compromised condition may be any of those disclosed above.
  • the treatment may be prophylactic, ameliorating or curative.
  • compositions and the pharmaceutical compositions according to the invention may also form part of a kit comprising said compositions and a dosage regime instruction with guidelines for dose and time administration.
  • the extracellular agents such as e.g. lentinan can be isolated from the extracellular growth medium following a fermentation of e.g. Lentinus fungal mycelium, or part thereof, in a liquid growth medium.
  • Isolation can occur by alcohol precipitation using 70% alcohol or 96% alcohol.
  • Suitable alcohols are C1 to C5 aliphatic alcohols, such as methanol, ethanol, propanol, iso-propanol, n-butanol, iso-butanol, n-pentanol.
  • the ratio between the volume of extracellular growth medium and alcohol can vary from 5:1 to 1:5, such as 4:1, 3.1, 2:1, 1:1, 1:2, 1:3, 1:4, and 1:5 depending on the concentration of alcohol and the length of the carbon chain.
  • a fraction of such agents including polysaccharides
  • Desalting can be carried out using a suitable column or by dialysis; suitable acidic solutions are diluted strong acids having a pH of from about 1 to about 7, such as a pH of from about 2 to about 6; suitable basic solutions are diluted strong bases having a pH of from about 7 to about 11, such as a pH of from about 8 to about 10.
  • Weak acids and weak bases can also be used for the washing step, as can 70% ethanol when e.g. 96% ethanol has been used for the precipitation.
  • Ion exchange chromatography and/or gel filtration are preferably used after desalting and/or washing of the precipitate.
  • fractions comprising extracellular agents having a molecular weight of from about 10,000 g/mol to about 20,000 g/mol, extracellular agents having a molecular weight of from about 20,000 g/mol to about 40,000 g/mol, extracellular agents having a molecular weight of from about 40,000 g/mol to about 60,000 g/mol, extracellular agents having a molecular weight of from about 60,000 g/mol to about 80,000 g/mol, extracellular agents having a molecular weight of from about 80,000 g/mol to about 100,000 g/mol, extracellular agents having a molecular weight of from about 100,000 g/mol to about 150,000 g/mol, extracellular agents having a molecular weight of from about 150,000 g/mol to about 200,000 g/mol, extracellular agents having a molecular weight of from about 200,000 g/mol to about
  • the purification can also involve steps actively seeking to remove e.g. proteinacious substances from e.g. a polysaccharide fraction. This can be achieved by proteolytic degradation by e.g. proteinase K. Lipids can be removed from a fraction by treatment with lipase or esterase. Undesirable polysaccharides can be removed by treatment with enzymes such as glucanases, amylases, and the like.
  • the purity of an isolated fraction of extracellular agents can be determined by e.g. chromatography or spectroscopy.
  • a medium composed of glucose, malt extract, yeast extract and peptone in various concentrations was used for cultivating Lentinus edodes for achieving fungus growth and lentinan production in 500 ml shake flasks containing 200 ml of medium.
  • the content of the various media is shown in Table 2. The flasks were shaken for 16 days at 28 degrees Centigrade.
  • the present results show that by changing the amount of inoculation material used and the composition of the fermentation medium, it is possible to affect the growth of Lentinus edodes and lentinan production.
  • the present experiments were carried out in a 10-litre reactor but there is no reason for restricting the process to the mentioned size.
  • the medium may contain malt extract, yeast extract, peptone and glucose.
  • the results show that there may be a relation between medium composition and production of lentinan.
  • the first filtrate after the fermentation went though the same steps from reducing the volume by boiling onwards.
  • the only step the extracellular product did not go through was being kept at 121° C. for two hours.
  • lentinan is a very active stimulator of the immune system.
  • the extracellular product provides a higher response than intracellular lentinan. It is, therefore, desirable to optimise the fermentation process for the production of extracellular lentinan. Extraction of intracellular lentinan is costly with respect to time, personnel and chemicals. It is, however, very simple to remove the extracellular product from the fermentation broth as methods for the precipitation of a polysaccharide can be used, for example by means of various types of alcohol.
  • a medium composed of 15 g/l glucose, 3 ⁇ l malt extract, 3 g/l yeast extract and 5 g/l peptone was used for cultivating Lentinus edodes to obtain fungus growth and lentinane production in 500-ml shake flasks containing 200 ml of medium. The flasks were shaken at 28 degrees Centigrade for a given number of days and the concentration of biomass and lentinan, respectively was measured. Typical results are given in Table 7 given below. TABLE 7 Shake Flask Experiments Biomass Extracellular Product Fermentation time (g/l) (g/l) (days) 1.33 65 14 5.0 53 22
  • the experiments were carried out in a 3-litre and a 10-litre bioreactor with stirring equipment.
  • the reactor was sterilized and filled with 2 and 6 litres of sterile medium, respectively.
  • the reactor was inoculated with the content of 7-8 days old shake flasks. Air was supplied to the reactors and the stirring equipment performed a good mixing of the reactor content.
  • the temperature was kept at 28 degrees Centigrade. In the experiments reported here, the fermentation time was 7 days unless otherwise stated.
  • the concentration of biomass dry weight
  • the concentration of isolated dried polysaccharide can be 200 mg/l.
  • Typical results are given in Table 2. TABLE 8 Typical Results from Bioreactor Experiment Biomass Extracellular (g/l) Product (mg/l) Comments 2.5 100 Glucose-based medium 1.6 140 Sucrose-based medium

Abstract

A process is described for the production of an immunostimulant by submerged cultivation of Lentinus edodes in which mycelium from agar plates or a fermentation broth is added to a liquid medium in a shake flask or a bioreactor containing nutrients such as malt extract, yeast extract, peptone and glucose having access to air or to which air is added, and which is kept in constant movement at approx. 28° C. At the proper conditions, there will be an increase in the production of extracellular lentinan, which is shown to be a better immunostimulant than intracellular lentinan. The extracellular product is precipitated from the growth medium by means of methods for the precipitation of microbial polysaccharide.

Description

    TECHNICAL AREA OF THE INVENTION
  • The present invention is directed to a method for producing an immune stimulant in liquid culture. The invention is in one embodiment directed to culturing Lentinus edodes under particular conditions in a fermentation broth. This application is a non-provisional claiming priority from Norwegian patent application No. NO 2001 4256 filed 3 Sep. 2001, which is hereby incorporated by reference in its entirety. All patent and non-patent references cited in that application, or in the present application, are also hereby incorporated by reference in their entirety.
  • BACKGROUND OF THE INVENTION
  • It is known that health-promoting effects are attributed to glucans from fungi and yeasts. “Shiitake” fungus (Lentinus edodes) has been attributed effects which can be exploited for many medicinal purposes such as immunestimulation, anti-virus, anti-tumour, etc. Studies of lentinan have shown that it stimulates the immune system of the host in a variety of ways, such as activation of T helper cells, increased production of Interleukin 1 and Interleukin 2, increased antibody production in various forms of cancer, and decreasing the cholesterol level in the blood. (Herbs for Health, January/February, 1997; K. Jones, “Shiitake: Medicine in a mushroom”, p. 40-50, 54; Anticancer Res, Vol. 17(4A), 1997; H. Matsouka, “Lentinan potentiates immunity and prolongs the survival time of some patients”, p. 2751-2755; Adv Appl Microbiol, Vol. 39, 1993; S. C. Jong, “Medicinal and therapeutic value of the shiitake mushroom”, p. 153-184, Int J Immunopharmacol, Vol. 14, 1992; K. Irinoda, “Stimulation of microbiocidal host defence mechanism against aerosol influenza virus infection by lentinan, p. 971-977., Jpn J Cancer Res, Vol. 76(1), 1985; D. Herlyn, “Monoclonal antibody-dependent murine macrophage-mediated cytotoxicity against human tumors is stimulated by lentinan, p. 37-42).
  • One active ingredient of Lentinus edodes is termed lentinan, a polysaccharide based compound described as a beta-(1,3) glucan backbone With beta-(1,6) side chains.
  • “Solid-state” reactors are routinely used for culturing fungi such as Lentinus edodes. This is a technology which is used for many purposes such as composting, production of biological products such as enzymes, soy sauce, acetic acid, and the like.
  • For the production of lentinan, Lentinus edodes can be cultivated on a suitable solid matrix provided by stems of tree or chips of wood to which is often added chemical compounds supporting the growth of mycelium and development of the fruiting bodies, where most of the lentinan is localised. The fruiting bodies are harvested, either by hand or mechanically, and are subsequently dried and ground to a powder which can be used as it is, or used in tablets, or sent for further processing such as extraction of lentinan.
  • The methods used for culturing fungi such as Lentinus edodes, harvesting and subsequently drying the fruiting bodies, and optionally extraction of lentinan, are well known for the skilled person. The cultivation time can be from four to ten weeks with few possibilities for controlling the process. This results in a fungal growth, and in turn, in an amount of lentinan produced which is not the same for each batch carried out. Also, extraction of lentinan from the fungal material is time consuming and process intensive.
  • Kim et al. (2001, Biotechnology Letters, 23, 513-517) describes extracellular polysaccharides produced by Phellinus lintus in submerged culture; Kim et al. (2002: Letters in Applied Microbiology, 34, 56-61) describes mycelial growth and exobiopolymer production by submerged culture of various edible mushrooms. There is no data available to indicate that any of these extracellular polymers are immune stimulating.
  • It is generally known to grow mycelium of Basidiomycetes in submerged culture and to obtain active ingredients from the growth medium, see e.g. Aouadi et al 1992 (Carbohydr Polym 17:177-184) and Lee et al 1995 (Prog Plant Polym Carbohydr Res, B. Behrs Verlag, Hamburg Del.) and Hatvani 2001 (Int J Antimicrob Agents 17:71-). However, none of the references discloses the isolation of extracellular components with immune stimulating activities. Furthermore, none of the references disclose that extracellular polysaccharides have different activities from their intracellular counterparts.
  • It is therefore an object of the present invention to provide novel methods for production of extracellular immune stimulating agents with higher level of activity than the hitherto known intracellular counterparts.
  • SUMMARY OF THE INVENTION
  • The invention in a first aspect, relates to a method for cultivating a fungal mycelium, preferably a fungus from the class of basidiomycetes, such as a fungus of the genus Lentinus, such as Lentinus edodes, in a liquid medium of sterile water to which nutrient compounds are added in predetermined concentrations. The liquid medium supports fungal growth and stimulates the production of extracellular compounds, such as immune stimulating agents, such as lentinan produced by fungal mycelium of the genus Lentinus, such as e.g. Lentinus edodes.
  • By fungal mycelium is intended any fungal biomass, which can be grown in submerged culture according to the invention. The fungal biomass may be in the form of single hyphae, spores, aggregates of mycelium, and partly differentiated mycelium.
  • Lentinan as used herein refers to the polysaccharide, which can be isolated from Lentinus edodes (Berk.) Sing. The primary structure is a β1,3-D-glucan having 2 β-1,6-glucopyranoside branchings for every 5 β-1,3 linear linkages. The molecular weight may vary from 400,000 to 800,000 (Merck Index 12th Edition, 1996, Monograph No 5462).
  • The cultivation of the fungal mycelium, such as fungi of the genus Lentinus, such as Lentinus edodes, results in the production of one or more extracellular agents, such as e.g. immune stimulating agents, in the form of e.g. a polysaccharide, such as e.g. a beta-glucan, including lentinan isolatable from Lentinus edodes, a polypeptide, a glycosylated polypeptide or a proteinacious polysaccharide compound, a proteoglucan, such as e.g. a polypeptide associated alpha-glucan or a polypeptide associated alpha-mannan, including KS-2 isolatable from Lentinus edodes, a lipid, or a secondary metabolite, which can be isolated and/or purified, and optionally fractionated, from the extracellular fraction of the fermentation broth of a bioreactor following cultivation of the basidiomycete fungal mycelium in question.
  • The extracellular fraction of the liquid fermentation medium is also termed the supernatant and this fraction can be separated from the fungal mycelium by e.g. centrifugation or filtration, or indeed by any other means available for obtaining a liquid fraction essentially without any fungal mycelium present therein. The term “essentially without any fungal mycelium present therein” shall denote that the concentration of fungal mycelium, including fractions thereof, has been reduced at least by a factor of 103, such as reduced by a factor of at least 104, for example a factor of at least 105, such as reduced by a factor of at least 106.
  • Besides being easier to isolate and process, fungal extracellular agents such as immune stimulating agents according to the present invention are surprisingly more potent than fungal associated agents, i.e. agents being either fungal intracellular agents, or agents which are removed from a liquid fermentation broth along with the removal of the fungal mycelium and fractions thereof by filtration, precipitation, or otherwise.
  • In a further aspect the invention relates to an immune stimulating agent obtainable from the extracellular part of the liquid growth medium according to the method of producing said immune stimulating agent.
  • This immune stimulating agent has surprisingly turned out to have a higher immunostimulating activity than the corresponding extract obtainable from the mycelium of the fungus, although the mycelium is known as the primary source of e.g. lentinan. In a particularly preferred embodiment, this extract is obtainable by removal of mycelium, removal of water from the medium, one or more rounds of precipitation with alcohol and washing with acid and/or base.
  • According to the invention there is also provided a composition comprising the immune stimulating agent obtainable as described above and a physiologically acceptable carrier. Furthermore, there is provided a pharmaceutical composition comprising the immune stimulating agent according to the invention and a pharmaceutically acceptable carrier. The pharmaceutical composition may in particular be used for treatment or prophylaxis in connection with an immune compromised condition.
  • Fungi belonging to the genus of Lentinus, such as Lentinus edodes, represent one example of fungi according to the present invention. In other preferred aspects of the invention a method is provided wherein the fungus is selected from the group of fungi consisting of Auricularia auricula-judae, Coriolus versicolor, Grifola frondosa, Flammulina velutipes, Schizophyllum commune, Sclerotinia scleroticum, Trametes versicolor, Tremella fuciformis, Agaricus blazei, Cordyceps sinensis, Ganoderma lucidum, Hericium erinaceus, lonotus obliquus, Pleurotus ostreatus, and Polyperus umbellatus.
  • DETAILED DESCRIPTION OF THE INVENTION
  • For the method of the present invention, “liquid-state” cultivation of Lentinus mycelium, or fractions thereof, is used. In short, this involves dissolving in water the nutrient compounds a microbial organism such as fungal mycelium, or fractions thereof, require for growth, transferring the solution to a bioreactor and inoculating the bioreactor with cells or spores of the microbial organism such as a fungal mycelium, or fractions thereof, to be cultivated. This is done under sterile conditions and with control of the environment in order to give the microbial organism a suitable chemical and physical environment. The technology related to “liquid-state” cultivation of microbial organisms is well known for the skilled person.
  • The advantage of “liquid-state” as compared to “semi-solid-state” or “solid-state” cultivation is that “liquid-state” proceeds more rapidly, is more effective with respect to conversion of the raw materials to products, and most importantly, it offers greater possibilities for controlling the growth conditions and thereby the reproducibility and the predictability of the process.
  • What distinguishes the various “liquid-state” processes from one another is the microbial organisms which are used and the cultivation conditions. For production of lentinan the microbial organism will be Lentinus edodes which is cultivated under the conditions described below. During “liquid-state” culture the medium with the fungal biomass is preferably agitated to reduce the occurrence of gradients and to ensure oxygen availability to the submerged cells. When microbial organisms are grown in a bioreactor, oxygen may be supplied to the liquid medium and the level of dissolved oxygen may be controlled by known methods.
  • Provided in one preferred embodiment is a method for production of lentinan, characterised by cultivating mycelium from Lentinus edodes in a liquid growth medium comprising one or more typical ingredients required for growth of microbial organisms such as malt extract, yeast extract, peptone, glucose, sucrose, salts providing phosphate, magnesium and potassium, corn-steep liquor and vitamins such as thiamine. More preferably, the medium comprises malt extract, yeast extract, peptone and glucose for mycelium growth and production of lentinan.
  • For inoculation of the growth medium, Lentinus edodes mycelium from agar plates containing malt extract, yeast extract, peptone and glucose can be used. Lentinus edodes can initially be cultivated on agar plates comprising the above nutrient compounds supporting the growth of the fungus. The plates are inoculated with mycelium from Lentinus edodes and incubated at least until a visible growth is evident on the plates, this can take from about 7 days to about 24 days or from about 10 to 30 days, typically 14 days or up to 20 days, at a temperature in the range of from 18 to 32° C., preferably in the area of from 22 to 31° C., such as a temperature of about 23° C., for example 24° C., such as 25° C., for example 26° C., such as 27° C., for example 28° C., such as 29° C., for example 30° C. The temperature may also be from 18 to 37° C., preferably from 23 to 32° C. such as about 28° C.
  • As an alternative to inoculation with mycelium from agar plates, inoculation of the growth medium can be carried out by using Lentinus edodes mycelium from a fermentation broth in e.g. a shake flask medium comprising nutrient compounds supporting cell growth. Shake flasks for cultivating Lentinus edodes can initially be inoculated with the mycelium which is cultivated on agar plates. The mycelium is scraped off the plates and transferred aseptically to shake flasks containing sterile water comprising dissolved nutrient compounds and nutrient salts supporting the growth of the fungal mycelium. A typical growth medium contains glucose, peptone, yeast extract and malt extract. The amount of inoculation material which gives the highest production of extracellular lentinan can be selected following initial experiments.
  • The shake flasks can be incubated by shaking for 6 to 21 days, preferably from 7 to 18 days, more preferably from 8 to 14 days at a temperature in the range of from 18 to 32° C., preferably in the area of from 22 to 31° C., such as a temperature of about 23° C., for example 24° C., such as 25° C., for example 26° C., such as 27° C., for example 28° C., such as 29° C., for example 30° C. The shake flasks may also be incubated from 8-25 days, more preferably from 10-20 days, more preferably from 12-18 days. The temperature may also be from 18 to 37° C., preferably from 23 to 32° C. such as about 28° C.
  • The content of the shake flasks can be used for inoculating a bioreactor. In that case, the reactor comprises a sterile solution of nutrient compounds and nutrient salts in water for mono-culture cultivation of basidiomycete fungal mycelium, or fractions thereof, such as Lentinus fungal mycelium, such as Lentinus edodes.
  • The bioreactor fermentation period is typically in the range of from 50 hours to 300 hours, preferably in the range of from 80 hours to 270 hours, and the temperature is kept constant in the range of 18 to 32° C., preferably in the area of from 22 to 31° C., such as a temperature of about 23° C., for example 24° C., such as 25° C., for example 26° C., such as 27° C., for example 28° C., such as 29° C., for example 30° C. The temperature may also be from 18 to 37° C., preferably from 23 to 32° C. such as about 28° C.
  • The reactor is fitted with an inlet for supplying air to the fermentation broth, and the fermentation broth is preferably kept under continuous agitation either as a result of the addition of air, or by means of a mixer device suitable for providing a good mixing of the content of the reactor.
  • It is preferred to adjust the pH of the growth medium to from about 3 to about 7, such as a pH of from about 4.5 to about 6.5, for example a pH of about 6, before the growth medium is inoculated with fungal mycelium, or fractions thereof, such as L. edodes mycelium. After the initial adjustment, pH may be dropped naturally during the course of the fermentation, or controlled at a particular value in the range pH 3 to 7, using addition of suitable pH-control agents, such as acid and base. The temperature of the growth medium is preferably in the range of from 18 to 32° C., preferably in the area of from 22 to 31° C., such as a temperature of about 23° C., for example 24° C., such as 25° C., for example 26° C., such as 27° C., for example 28° C., such as 29° C., for example 30° C. The temperature may also be from 18 to 37° C., preferably from 23 to 32° C. such as about 28° C.
  • Samples can be obtained from the bioreactor and analysed for biomass, metabolic products and nutrient compounds, the determinations of which can assist the operator of the bioreactor in the running of the fermentation process. Typical analyses routinely carried out are determination of biomass, residual sugar concentration and extracellular agent concentration, such as lentinan concentration in the case of Lentinus including Lentinus edodes. A person skilled in the art knows the methods for analysis which can be employed in this respect.
  • In the case of cultivation of Lentinus edodes, extracellular lentinan may be removed from the liquid growth medium by precipitation with e.g. alcohol, or by other means which result in the isolation and/or purification of microbial polysaccharides. It is an important aspect of the present invention that such isolation from the growth medium is performed with gentle methods and is generally carried out at temperatures around room temperature. Therefore the extracted compounds are not degraded or converted as may often be the case when using harsh extraction conditions for extracting compounds from the mycelium or from the fruiting bodies of Lentinus edodes.
  • Lentinus edodes deposited under IHEM 18992 with the Belgian Coordinated Collections of Microorganism (BCCM), 14 Rue J. Wytsman, B-1050 Bruxelles, Belgium, represents one preferred strain of Lentinus edodes. Further strains of Lentinus edodes are available from culture collections such as ATCC (American Type Culture Collection, P.O. Box 1549, Manassas, Va. 20108, USA), CBC (Centraalbureau voor Schimmelcultures, PO Box 85167, 3508 AD Utrecht, THE NETHERLANDS) and DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, 38124 Braunschweig GERMANY). Additionally relevant Lentinus species, besides Lentinus edodes, includes Lentinus species such as: Lentinus albovelutinus G. Stev. (1964)=Rhodocybe albovelutina (G. Stev.) E. Horak (1971); Lentinus anthocephalus (Lév.) Pegler; Lentinus badius Bres.; Lentinus castoreus Fr. (1838)=Lentinellus ursinus (Fr.) Kühner (1926); Lentinus chrysopeplus Berk. & M. A. Curtis (1869)=Cyptotrama asprata (Berk.) Redhead & Ginns (1980); Lentinus cochleatus Fr.; Lentinus concinnus Pat.; Lentinus delicatus G. Stev. (1964)=Marasmius delicatus (G. Stev.) E. Horak (1971); Lentinus fasciatus Berk.; Lentinus hepatotrichus Berk. (1859)=Lentinellus ursinus (Fr.) Kühner (1926); Lentinus hyracinus Kalchbr. (1880)=Lentinellus ursinus (Fr.) Kühner (1926); Lentinus lepideus sensu Colenso (1891); Lentinus lepideus (Fr.) Fr. (1825)=Lentinus suffrutescens (Brot.) Fr. (1825); Lentinus novaezelandiae Berk. (1855)=Lentinellus ursinus (Fr.) Kühner (1926); Lentinus pulvinulus Berk. (1859)=Lentinellus pulvinulus (Berk.) Pegler (1965); Lentinus punctaticeps Berk. & Broome (1883); Lentinus punctaticeps cf. sensu Petersen, Nicholl & Hughes (1997); Lentinus pygmaeus Colenso (1887)=Lentinus zelandicus Sacc. & Cub. (1887); Lentinus sajor-caju (Fr.) Fr.; Lentinus squarrulosus Mont.; Lentinus strigosus (Schwein.) Fr. (1825); Lentinus suffrutescens (Brot.) Fr. (1825); and Lentinus tuber-regium Fr.; Lentinus zelandicus Sacc. & Cub. (1887) (Ref: http://nzfungi.landcareresearch.co.nz).
  • Fungal Mycelium Extracellular Immunostimulants
  • Provided in one embodiment of the invention is an immune stimulating agent, preferably a polysaccharide or a glycosylated polypeptide, obtained from the cultivation of basidiomycete fungal mycelium such as Lentinus mycelium according to the method of the invention.
  • Provided in another embodiment of the invention is the use of an extracellular agent such as lentinan in a method for stimulating the immune system of an individual in need of such stimulation. The lentinan is administered e.g. orally or subcutaneously to the individual in a pharmaceutically effective amount capable of stimulating the immune system of the individual. The stimulation of the immune system can be demonstrated by e.g. increased antibody production, by activation of helper T-cells, or by increased production of interleukins such as Interleukin 1 and Interleukin 2.
  • Provided in yet another embodiment of the invention is the use of an extracellular agent such as lentinan in the manufacture of a medicament for treating an immune compromised condition in an individual in need of such treatment. An immune compromised condition in an individual is demonstrated e.g. by an insufficient amount of antibodies, or a decreased antibody production, by an insufficient amount of helper T-cells, or a decreased production of helper T-cells in the individual, or by an insufficient amount of interleukins such as Interleukin 1 and Interleukin 2, or a decreased production of interleukins such as Interleukin 1 and Interleukin 2 in the individual.
  • “Insufficient amount” and “decreased production” as used herein above shall denote such amounts and productions which a medical expert considers as being below a predetermined level or value normally associated with a healthy individual. The amount and/or production will generally depend on factors such as age, general physical condition, and the like. For this reason a predetermined level or value shall be determined oh an individual basis by a medical expert. One indication of an immune compromised condition in an individual is a gradually decreasing number of antibodies, a gradually decreasing number of CD4 (positive) cells, or a gradually decreasing number of T-helper cells per unit (blood) sample volume measured over time, such as days, weeks, months or years.
  • Additional examples of extracellular immunostimulants includes, but is not limited to, β-(1,3), β-(1,6) D-glucans, schizophyllan, grifolan, coriolan and Coriolus versicolor glycosylated polypeptides such as PSK and PSP, polypeptides associated with alpha-mannan such as KS-2 isolatable from Lentinus edodes, and reishi isolatable from Ganoderma lucidum. Reference is made to Table 1 herein below for a further detailed description of the structure and composition of the above extracellular immunostimulants.
  • Preferred immunostimulating agents produced by fungal mycelium of the invention are polysaccharides such as polysaccharides comprising a β-D-glucan backbone (i.e. linear polymers of D-glucose with other monosaccharides), or β-D-glucans linked to proteins (so-called polysaccharide-peptides, or “proteoglucans”). The preferred polysaccharides are homopolymers. The basic β-D-glucan is a repeating structure with its D-glucose molecule joined by linear chains by β-bonds from the carbon 1 of one saccharide ring to the carbon 3 of the next (β-1,3), from carbon 1 to carbon 4 (β-1,4), or from carbon 1 to carbon 6 (β-1,6). The best know immune stimulating compound produced by Lentinus edodes is lentinan. This is β-(1,3) D-glucan with β-(1,6) side chains. The chain length varies with the typical product having a molecular weight in the range 400,000-1,000,000 g/mol. Further preferred polysaccharides are listed in Table 1.
  • For a determination of the immunostimulating characteristics of an extracellular agent such as e.g. lentinan, the following method can be used: 12 weeks old Sprague Dawley rats receive 1 mg of test compound which have been extracted from the fermentation broth in 0.5 ml 0.09 saline (i.p.) 2 days before the immunisation. Control animals receive 1 mg casein. The animals are immunised with BSA (0.5 mg) in 0.25 “Freunds Complete Adjuvant” and blood samples are obtained after 11 days for measurement of the antibody response. The specific anti-BSA antibody concentration is determined against an absolute standard of antibody BSA by means of “sandwich” ELISA. A typical result of the immuno-stimulating activity of intracellular and extracellular lentinan is shown in Table 7a and 7b.
  • Additional Fungal Mycelium Extracellular Agents and Uses Thereof
  • Further additional preferred embodiments of the present invention relate to extracellular agents, other than immunostimulating agents, produced by a number of fungi, as well as to methods for producing said agents and methods for using said agents.
  • The fungi of particular interest to the present invention include Lentinus edodes, Ganoderma lucidum, Auricularia auricula-judae, Coriolus versicolor, Grifola frondosa, Flammulina velutipes, Schizophyllum commune, Sclerotinia scleroticum, Trametes versicolor, Tremella fuciformis, Agaricus blazei, Cordyceps sinensis, Ganoderma lucidum, Hericium erinaceus, lonotus obliquus, Pleurotus ostreatus, and Polyperus umbellatus.
  • The above fungal mycelium can be cultivated in mono-culture in a bio-reactor under suitable growth conditions allowing growth and propagation of the fungal mycelium in question. The growth conditions cited herein for Lentinus edodes can also be used for the above fungal mycelium.
  • Besides extracellular fungal immune stimulating agents, such as extracellular proteinacious compounds, including glycosylated polypolypeptides, such as the alpha-mannan polypeptide KS-2, and extracellular polysaccharides, such as extracellular lentinan produced by Lentinus edodes, the fungal microbial organisms of the invention, such as e.g. Ganoderma lucidum, Auricularia auriculajudae, Coriolus versicolor, Grifola frondosa, Flammulina velutipes, Schizophyllum commune, Scierotinia scleroticum, Trametes versicolor, Tremella fuciformis, Agaricus blazei, Cordyceps sinensis, Ganoderma lucidum, Hericium erinaceus, lonotus obliquus, Pleurotus ostreatus, and Polyperus umbellatus are also capable of extracellularly producing agents having additional desirable effects.
    TABLE 1
    Extracellular agents, including structure and composition,
    produced by the selected fungi.
    Extracellular
    Fungus agent Structure and composition
    Schizophyllum schizophyllan β-(1,3), β-(1,6) D glucan
    commune
    Grifola frondosa grifolan β-(1,3), β-(1,6) D glucan
    Coriolus versicolor PSK, PSP Polypeptides attached to
    polysaccaride β-D glucan chains.
    The polysaccharide chains are
    true glucans, mainly 1,4; 1,2 and
    1,3 glucose linkages
    Lentinus edodes KS-2 Polypeptide associated α-mannan
    Lentinus edodes lentinan β-(1,3), β-(1,6) D glucan
    Ganoderma lucidum reishi The basic structure of the major
    bioactive Ganoderma glucans β-
    (1,3), β-(1,6) D glucan is β-(1,3)D-
    glucopyronan with 1-5 units of β-
    (1,6) monoglucosyl side chains
  • The effects associated with the above extracellular agents produced by the fungi of the invention are e.g. analgesic effects, anti-allergic activity, bronchitis-preventative effects, anti-inflammatory activity, anti-bacterial properties (against Staphylococci, Streptococci and Bacillum pneumoniae), antioxidant effects, antitumor activity, blood pressure lowering effects, bone marrow formation enhancing effects, cardiotonic activity (i.e. lowering serum cholesterol and/or increasing myocardial metabolism and/or improving coronary artery hemodynamics), natural killer cell enhancing effects, expectorant and antitussive properties, immunopotentiation activities, anti-HIV activities, adrenocortical improving effects, Interleukin-1, Interleukin-2, and Interleukin-3 stimulating effects, liver-protective effects and detoxifying effects, ionizing radiation protecting effects, anti-ulcer activity, and agents having the effect of increasing white blood cells and hematoglobin in peripheral blood.
  • The above effects can be demonstrated clinically in animals including human beings having been treated with a pharmaceutically effective amount of an extracellular agent isolated from a fungal mycelium according to the invention.
  • Method of Treatment
  • In one aspect the invention relates to a method of treatment of an individual diagnosed with an immune compromised condition, said method comprising the steps of administering to said individual the composition according to the invention or the pharmaceutical composition according to the invention in an amount effective in treating said immune compromised condition.
  • The administered amount may in be an amount effective in prophylactically treating said immune compromised condition.
  • Also provided is a method of treatment of an individual recovering from surgery or illness and at risk of contracting an immune compromised condition, said method comprising the steps of administering to said individual the composition according to the invention or the pharmaceutical composition according to the invention in an amount effective in boosting the immune system of said individual.
  • Furthermore a method of treatment of an individual diagnosed with or at risk of contracting acquired immunodeficiency syndrome is provided, said method comprising the steps of administering to said individual the composition according to the invention or the pharmaceutical composition according to the invention in an amount effective in treating or prophylactically treating said syndrome.
  • The immune compromised condition may be selected from the group consisting of an infectious disease, a parasitic disease, haemophilus meningitis, pneumococcal meningitis, streptococcal meningitis, staphylococcal meningitis, meningitis due to other organisms, encephalitis, viral pneumonia, pneumococcal pneumonia, other bacterial pneumonia, pneumonia due to other specified organisms except bacteria, bronchopneumonia, organism unspecific pneumonia, influenza, unspecified diarrhea, hepatitis unspecified, acute and subacute necrosis of the liver, chronic hepatitis, and abscess of liver.
  • Furthermore, the immune compromised condition may be an infectious or parasitic disease caused by, or selected from, cholera, salmonella, shigellosis, Escherichia coli, intestinal infection due to other specified bacteria, Clostridium difficile, viral gastroenteritis, infectious colitis, enteritis and gastroenteritis, infectious diarrhea, tuberculosis, listeriosis, pasteurellosis, mycobacterium, diphtheria, pertussis, meningococcus, streptococcus septicaemia, staphylococcus septicaemia, pneumococcal septicaemia, septicaemia due to anaerobes, septicaemia due to other gram-negative organisms, actinomycotic infection, gas gangrene, toxic shock syndrome, necrotizing faciitis, Friedlander's bacillus, haemophilus influenzae, pseudomonas, AIDS/HIV infections, acute poliomyelitis, Creutzfeldt-Jacob disease, subacute sclerosing panencephalitis, progressive multifocal leucoencephalopathy, unspecified slow virus infection of the central nervous system, coxsackie virus, unspecified viral meningitis, lymphocytic choriomeningitis, unspecified viral encephalitis, chickenpox, herpes zoster, herpes simplex, viral hepatitis ‘A’, viral hepatitis ‘B’, other specified viral hepatitis, chronic hepatitis, abscess/acute necrosis of liver, infectious mononucleosis, cytomegalic inclusion disease, chlamydiae, adenovirus, viral infection, syphilis, candida, unspecified histoplasmosis, aspergillosis, cryptococcosis, mycoses, strongyioidiasis, intestinal parasitism, toxoplasmosis, sarcoidosis, pneumocystis carinii, post polio syndrome, haemophilus meningitis, pneumococcal meningitis, streptococcal meningitis, staphylococcal meningitis, encephalitis, pneumonia due to adenovirus, pneumonia due to respiratory syncytial virus, pneumonia due to parainfluenza virus, pneumonia due to other virus, viral pneumonia, pneumococcal pneumonia, pneumonia due to klebsiella pneumoniae, pneumonia due to pseudomonas, pneumonia due to haemophilus influenzae, pneumonia due to streptococcus, pneumonia due to staphylococcus, and bacterial pneumonia.
  • The individual may be a mammal including a human being.
  • The pharmaceutical composition according to the invention may also be used in the manufacture of a medicament for treatment of an immune compromised condition of an individual in need of such treatment. The immune compromised condition may be any of those disclosed above. The treatment may be prophylactic, ameliorating or curative.
  • The composition and the pharmaceutical compositions according to the invention may also form part of a kit comprising said compositions and a dosage regime instruction with guidelines for dose and time administration.
  • Purification and Isolation of Extracellular Agents
  • The extracellular agents such as e.g. lentinan can be isolated from the extracellular growth medium following a fermentation of e.g. Lentinus fungal mycelium, or part thereof, in a liquid growth medium.
  • Isolation can occur by alcohol precipitation using 70% alcohol or 96% alcohol. Suitable alcohols are C1 to C5 aliphatic alcohols, such as methanol, ethanol, propanol, iso-propanol, n-butanol, iso-butanol, n-pentanol. The ratio between the volume of extracellular growth medium and alcohol can vary from 5:1 to 1:5, such as 4:1, 3.1, 2:1, 1:1, 1:2, 1:3, 1:4, and 1:5 depending on the concentration of alcohol and the length of the carbon chain.
  • It is also possible to obtain from the precipitated fraction of extracellular agents a fraction of such agents, including polysaccharides, by subjecting the alcohol precipitated extracellular agents such as polysaccharides to one or more steps selected from desalting, washing with an acidic solution, washing with a basic solution, ion exchange chromatography, and gel filtration, including any combination thereof. Desalting can be carried out using a suitable column or by dialysis; suitable acidic solutions are diluted strong acids having a pH of from about 1 to about 7, such as a pH of from about 2 to about 6; suitable basic solutions are diluted strong bases having a pH of from about 7 to about 11, such as a pH of from about 8 to about 10. Weak acids and weak bases can also be used for the washing step, as can 70% ethanol when e.g. 96% ethanol has been used for the precipitation.
  • Ion exchange chromatography and/or gel filtration are preferably used after desalting and/or washing of the precipitate. By using such steps, one can obtain fractions comprising extracellular agents having a molecular weight of from about 10,000 g/mol to about 20,000 g/mol, extracellular agents having a molecular weight of from about 20,000 g/mol to about 40,000 g/mol, extracellular agents having a molecular weight of from about 40,000 g/mol to about 60,000 g/mol, extracellular agents having a molecular weight of from about 60,000 g/mol to about 80,000 g/mol, extracellular agents having a molecular weight of from about 80,000 g/mol to about 100,000 g/mol, extracellular agents having a molecular weight of from about 100,000 g/mol to about 150,000 g/mol, extracellular agents having a molecular weight of from about 150,000 g/mol to about 200,000 g/mol, extracellular agents having a molecular weight of from about 200,000 g/mol to about 300,000 g/mol, extracellular agents having a molecular weight of from about 300,000 g/mol to about 400,000 g/mol, extracellular agents having a molecular weight of from about 400,000 g/mol to about 500,000 g/mol, extracellular agents having a molecular weight of from about 500,000 g/mol to about 600,000 g/mol, extracellular agents having a molecular weight of from about 600,000 g/mol to about 700,000 g/mol, extracellular agents having a molecular weight of from about 700,000 g/mol to about 800,000 g/mol, extracellular agents having a molecular weight of from about 800,000 g/mol to about 900,000 g/mol, and extracellular agents having a molecular weight of from about 900,000 g/mol to about 1,000,000 g/mol.
  • The purification can also involve steps actively seeking to remove e.g. proteinacious substances from e.g. a polysaccharide fraction. This can be achieved by proteolytic degradation by e.g. proteinase K. Lipids can be removed from a fraction by treatment with lipase or esterase. Undesirable polysaccharides can be removed by treatment with enzymes such as glucanases, amylases, and the like.
  • The purity of an isolated fraction of extracellular agents can be determined by e.g. chromatography or spectroscopy.
  • One way to isolate an extracellular agent is to modify the method described by Chihara et at (1970): Fractionation and purification of the polysaccharide with marked antitumor activity, especially lentinan from Lentinus edodes (Berk) Sing. (An edible mushroom). Cancer research, 30, 2776-2781. According to the present invention, fungal biomass is removed from the broth with filtration and the volume of the filtrate reduced to 10-20% of the original volume by evaporation. A solvent is then added to the concentrated liquid until precipitation of the product is achieved. Solvents include alcohols such as methanol, ethanol, butanols and propanols, as well as various ketones. The precipitate is re-suspended and washed with alkali and acids as well as the solvent before final drying.
  • EXAMPLES
  • The following examples illustrate preferred embodiments of the invention and should not be construed so as to limit the invention to the embodiments and technical results disclosed in the examples.
  • Example 1 Shake Flask Experiments
  • A medium composed of glucose, malt extract, yeast extract and peptone in various concentrations was used for cultivating Lentinus edodes for achieving fungus growth and lentinan production in 500 ml shake flasks containing 200 ml of medium. The content of the various media is shown in Table 2. The flasks were shaken for 16 days at 28 degrees Centigrade.
    TABLE 2
    Composition of media for shake flask experiments
    Malt extract Yeast extract Peptone Glucose
    Medium (%) (%) (%) (%)
    1 0.3 0.3 0.5 1.0
    2 0.3 0 0.5 1.0
    3 0 0.3 0.5 1.0
    4 1.0 0.3 0.5 0
    5 0.3 0.3 0.5 2.0
    6 0.3 0.3 0.5 4.0
    7 0 0 0.5 1.0
  • All media are adjusted to pH 6
  • The resulting production of fungus mass and lentinan is shown in Table 3:
    Medium Biomass (g/l) Lentinan (mg/l)
    1 2.4 42
    2 0.9 15
    3 1.1 14
    4 0.2 0
    5 2.3 43
    6 1.8 33
    7 0.3 0
  • The maximum amount of biomass and lentinan was produced when all medium components were present. Omission of one of the components resulted in reduced growth and lentinan production. The same thing happened if the concentration of glucose became too high.
  • Example 2 Bioreactor Experiments
  • For these experiments, a 10-litre bioreactor with stirring equipment was used. The reactor was sterilized and filled with 6 litres of sterile medium. After pH adjustment to a value of about 6, the reactor was inoculated with the content of 16 days old shake flasks. Air was added to the reactors at a rate of 1 vvm (volume of air per volume of reactor per minute), the stirrer rotated at a rate of 200 rpm and the temperature was kept at approx. 28 degrees Centigrade.
  • A. Media Compositions
  • The various media used are shown in Table 4.
    TABLE 4
    Composition of media used in bioreactor experiments
    Malt extract Yeast extract Peptone Glucose
    Medium (%) (%) (%) %
    A 0.3 0.3 0.5 1.0
    B 0.3 0.3 0.5 2.0
    C 0.3 0.3 1.0 1.0
  • The resulting concentration of biomass and lentinan achieved is shown in Table 5.
    TABLE 5
    Biomass and lentinan in a bioreactor with different media
    Fermentation time1 Biomass Lentinan
    Medium (hours) (g/l) (g/l)2
    A 88 3.97 0.17
    B 240 3.62 0.23
    C 211 3.48 0.10

    1For maximum lentinan concentration

    2Containing extracellular as well as extracted intracellular lentinan.
  • Apparently, there is little variation in the produced amount of biomass and lentinan achieved by means of the different media. It was observed, however, that the lag time of the fermentation process was considerable. This is unproductive time and it is usual practice to reduce the lag time by varying the amount of inoculation material used.
  • B. Variation of Amount of Inoculation Material Used in Bioreactor Experiments.
  • The result of using different amounts of inoculation material is shown in Table 6:
    TABLE 6
    Production of biomass and lentinan in a bioreactor
    with different amounts of inoculation material
    Amount of Fermentation time1 Biomass Lentinan
    inoculum (%) (hours) (g/l) (g/l)2
    15 144 3.07 0.07
    30 88 3.97 0.17

    1For maximum lentinan concentration

    2Contains extracellular as well as extracted intracellular lentinan
  • The present results show that by changing the amount of inoculation material used and the composition of the fermentation medium, it is possible to affect the growth of Lentinus edodes and lentinan production. We have demonstrated that it is possible to upgrade the cultivation of L edodes from shake flasks to a bioreactor. The present experiments were carried out in a 10-litre reactor but there is no reason for restricting the process to the mentioned size.
  • The experiments show that by varying the amount of inoculation material, it is possible to affect both the lag time of the process and the amount of lentinan produced. Further experiments must be carried out for establishing the optimal amount of inoculation material.
  • The experiments with respect to the composition of nutrients in the growth medium show that for the growth of L edodes and the production of lentinan, the medium may contain malt extract, yeast extract, peptone and glucose. The results show that there may be a relation between medium composition and production of lentinan. By increasing the concentration of glucose to 2%, the lag time is increased but not the rate of growth. This increase of the lag time also occurred in the production of lentinan, the production starting later at a high concentration of glucose, but the amount of extracellular lentinan produced was increased.
  • Example 3 Immunological Experiments
  • The result of immunological experiments with even amounts of intracellular and extracellular material from the fermentation broth, used as described above, is presented in Table 7.
  • After fermentation the biomass was separated from the rest of the fermentation broth by filtration. It was then added to 1 litre of distilled water and this mixture was heated in an autoclave at 121° C. for two hours. The mixture was subsequently filtered and the volume of the filtrate was reduced by boiling to around 10% of the original volume. When this had cooled to room temperature, around 2 volumes of absolute ethanol was added to precipitate the product. The precipitate was removed and washed with absolute ethanol, resuspended in distilled water and homogenised. Thereafter, 200 ml of 0.2 M cetyltrimethyl ammonium bromide and 0.2 M sodium hydroxide was added and the mixture was stirred well and kept at 4° C. for 18 hours. The precipitate was thereafter removed and washed with absolute ethanol. Then, 50 ml of a 20% glacial acetic acid was added to the filtrate and the mixture was stirred. The precipitate was subsequently removed, washed well and dried under vacuum.
  • The first filtrate after the fermentation (fermentation broth less the biomass) went though the same steps from reducing the volume by boiling onwards. Thus the only step the extracellular product did not go through was being kept at 121° C. for two hours.
  • For a determination of the immunostimulating characteristics, the following method was used: 12 weeks old Sprague Dawley rats received 1 mg of test compound which had been extracted from the fermentation broth in 0.5 ml 0.09 saline (i.p.) 2 days before the immunisation. Control animals received 1 mg casein. The animals were immunised with BSA (0.5 mg) in 0.25 “Freunds Complete Adjuvant” and blood samples were obtained after 11 days for measurement of the antibody response. The specific anti-BSA antibody concentration was determined against an absolute standard of antibody BSA by means of “sandwich” ELISA.
    TABLE 7a
    Immune response (measured in anti-BSA Ig production)
    in rats treated with lentinan
    Anti-BSA Ig
    Sample (μg/ml serum)
    Control 9
    Intracellular lentinan 19
    Extracellular lentinan 24
  • TABLE 7b
    Immune response (measured in anti-BSA Ig production)
    in rats treated with lentinan (corrected numbers)
    anti-BSA Ig
    Treatment (μg/ml serum)
    Control 9
    Cellular lentinan 16
    Ekstracellular lentinan 26
  • The data in Table 6b have been corrected.
  • The results of the immunological experiments shows that lentinan is a very active stimulator of the immune system. The extracellular product provides a higher response than intracellular lentinan. It is, therefore, desirable to optimise the fermentation process for the production of extracellular lentinan. Extraction of intracellular lentinan is costly with respect to time, personnel and chemicals. It is, however, very simple to remove the extracellular product from the fermentation broth as methods for the precipitation of a polysaccharide can be used, for example by means of various types of alcohol.
  • Example 4 Shake Flask Experiments
  • A medium composed of 15 g/l glucose, 3 μl malt extract, 3 g/l yeast extract and 5 g/l peptone was used for cultivating Lentinus edodes to obtain fungus growth and lentinane production in 500-ml shake flasks containing 200 ml of medium. The flasks were shaken at 28 degrees Centigrade for a given number of days and the concentration of biomass and lentinan, respectively was measured. Typical results are given in Table 7 given below.
    TABLE 7
    Shake Flask Experiments
    Biomass Extracellular Product Fermentation time
    (g/l) (g/l) (days)
    1.33 65 14
    5.0 53 22
  • Extending the fermentation time led to more biomass but the concentration of extracellular product did not show a concomitant increase. It may be that degradation of the product became more dominant during the extended fermentation time allowed.
  • Example 5 Bioreactor Experiments
  • The experiments were carried out in a 3-litre and a 10-litre bioreactor with stirring equipment. The reactor was sterilized and filled with 2 and 6 litres of sterile medium, respectively. Following pH adjustment to a value of about 6, the reactor was inoculated with the content of 7-8 days old shake flasks. Air was supplied to the reactors and the stirring equipment performed a good mixing of the reactor content. The temperature was kept at 28 degrees Centigrade. In the experiments reported here, the fermentation time was 7 days unless otherwise stated.
  • Under these conditions, the concentration of biomass (dry weight) can be up to 3 g/l and the concentration of isolated dried polysaccharide can be 200 mg/l. Typical results are given in Table 2.
    TABLE 8
    Typical Results from Bioreactor Experiment
    Biomass Extracellular
    (g/l) Product (mg/l) Comments
    2.5 100 Glucose-based medium
    1.6 140 Sucrose-based medium

Claims (30)

1. A method for producing an immune stimulating agent, said method comprising the steps of
i) cultivating a fungus selected from the group of fungal cells consisting of Agaricus blazei, Ganoderma lucidum, Schizophyllum commune and Coriolus versicolor,
wherein said cultivation results in extracellular accumulation of the immune stimulating agent, and
ii) isolating the extracellularly located immune stimulating agent from the liquid growth medium.
2. The method of claim 1, wherein the fungal cell is Agaricus blazei.
3. The method of claim 1, wherein the fungal cell is Ganoderma lucidum.
4. The method of claim 1, wherein the fungal cell is Schizophyllum commune.
5. The method of claim 1, wherein the fungal cell is Coriolus versicolor.
6. The method of claim 1, wherein the immune stimulating agent comprises a polysaccharide.
7. The method of claim 1, wherein the immune stimulating agent consists of a polysaccharide.
8. The method of claim 6, wherein the polysaccharide comprises a β-D-glucan backbone in the form of a linear polymer of D-glucose with other monosaccharides.
9. The method of claim 8, wherein the D-glucose residues are linked in beta-(1,3) configuration.
10. The method of claim 6, wherein the polysaccharide comprises a backbone of beta-(1,3)-glucosyl units.
11. The method of claim 6, wherein the polysaccharide comprises 2 glucose branches for every 5 beta-(1,3) glucosyl units in the backbone.
12. The method of claim 6, wherein the polysaccharide is a homopolymer.
13. The method of claim 6, wherein the polysaccharide has a molecular weight in the range of from 400,000 g/mol to about 1,000,000 g/mol.
14. The method of claim 1, wherein the immune stimulating agent is capable of stimulating in an individual in need of such stimulation, the production of one or more of antibodies, T helper cells, interleukins, interferon, natural killer cells, and macrophages.
15. The method of claim 1, wherein the liquid growth medium comprises one or more ingredients required for growth of microbial organisms selected from the group consisting of malt extract, yeast extract, peptone, glucose, sucrose, salts providing phosphate, magnesium and potassium, corn-steep liquor and vitamins such as thiamine.
16. The method of claim 1, wherein the liquid growth medium comprises one or more typical ingredients required for growth of microbial organisms selected from the group consisting of malt extract, yeast extract, peptone, and glucose.
17. The method of claim 1, wherein the liquid growth medium is agitated and supplied with an oxygen source.
18. The method of claim 1, wherein the growth temperature is in the range of from 23° C. to 32° C.
19. The method of claim 1, wherein the fungal mycelium, and fractions thereof, are removed from the liquid growth medium prior to the isolation of the immune stimulating agent.
20. The method of claim 19, wherein the fungal mycelium, and fractions thereof, are removed by filtration or centrifugation.
21. The method of claim 20, wherein the immune stimulating agent is precipitated by alcohol precipitation.
22. The method of claim 21, wherein the precipitated immune stimulating agent is further purified by washing and/or desalting.
23. The method of claim 21, wherein the precipitated immune stimulating agent is further purified by washing and ion-exchange chromatography.
24. The method of claim 22, wherein the precipitated immune stimulating agent is further purified by size exclusion chromatography or gel filtration.
25. The method of claim 1, wherein the extracellularly located immune stimulating agent isolatable from the liquid growth medium is also produced intracellularly in said fungal myclium.
26. The method of claim 25, wherein extracellularly located immune stimulating agent is immunologically distinct from intracellularly produced immune stimulating agent.
27. The method of claim 25, wherein the extracellularly located immune stimulating agent is more potent than a fungal associated, immune stimulating agent.
28. The method of claim 27, wherein the fungal associated, immune stimulating agent is removed from the liquid growth medium along with the removal of the fungal mycelium.
29. The method of claim 28, wherein the fungal mycelium is removed by by filtration or precipitation.
30. The method of claim 23, wherein the precipitated immune stimulating agent is further purified by size exclusion chromatography or gel filtration.
US11/305,136 2001-09-03 2005-12-19 Production of fungal extracellular immune stimulating compounds Abandoned US20060094689A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/305,136 US20060094689A1 (en) 2001-09-03 2005-12-19 Production of fungal extracellular immune stimulating compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NO20014256A NO20014256D0 (en) 2001-09-03 2001-09-03 Preparation of immunostimulatory compound
NONO20014256 2001-09-03
US10/488,427 US20050163800A1 (en) 2001-09-03 2002-09-03 Production of fungal extracellular immune stimulating compounds
US11/305,136 US20060094689A1 (en) 2001-09-03 2005-12-19 Production of fungal extracellular immune stimulating compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/488,427 Continuation US20050163800A1 (en) 2001-09-03 2002-09-03 Production of fungal extracellular immune stimulating compounds

Publications (1)

Publication Number Publication Date
US20060094689A1 true US20060094689A1 (en) 2006-05-04

Family

ID=19912789

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/488,427 Abandoned US20050163800A1 (en) 2001-09-03 2002-09-03 Production of fungal extracellular immune stimulating compounds
US11/305,136 Abandoned US20060094689A1 (en) 2001-09-03 2005-12-19 Production of fungal extracellular immune stimulating compounds
US12/896,726 Expired - Lifetime US8758768B2 (en) 2001-09-03 2010-10-01 Process for production of fungal extracellular immune stimulating compounds
US14/162,272 Expired - Fee Related US9249438B2 (en) 2001-09-03 2014-01-23 Production of fungal extracellular immune stimulating compounds
US15/008,891 Expired - Fee Related US10471135B2 (en) 2001-09-03 2016-01-28 Production of fungal extracellular immune stimulating compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/488,427 Abandoned US20050163800A1 (en) 2001-09-03 2002-09-03 Production of fungal extracellular immune stimulating compounds

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12/896,726 Expired - Lifetime US8758768B2 (en) 2001-09-03 2010-10-01 Process for production of fungal extracellular immune stimulating compounds
US14/162,272 Expired - Fee Related US9249438B2 (en) 2001-09-03 2014-01-23 Production of fungal extracellular immune stimulating compounds
US15/008,891 Expired - Fee Related US10471135B2 (en) 2001-09-03 2016-01-28 Production of fungal extracellular immune stimulating compounds

Country Status (5)

Country Link
US (5) US20050163800A1 (en)
EP (1) EP1451336B1 (en)
AU (1) AU2002328099A1 (en)
NO (1) NO20014256D0 (en)
WO (1) WO2003020944A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100021426A1 (en) * 2003-10-03 2010-01-28 Wang ya-chun Methods for making and compositions comprising fermentation products of cordyceps sinensis

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20014256D0 (en) 2001-09-03 2001-09-03 Bjoern Kristiansen Preparation of immunostimulatory compound
NO20044581L (en) * 2004-01-12 2005-07-13 Geir Hetland Use of the fungus Agaricus blazei Murill in the manufacture of medications to fight infections and allergies
US7514085B2 (en) * 2004-07-16 2009-04-07 Medimush A/S Immune modulating compounds from fungi
CA2574060C (en) * 2004-07-16 2019-06-25 Medimush A/S Immune modulating compounds from fungi
CN1296389C (en) * 2004-09-14 2007-01-24 武汉大学 Three spiral lentinan with anti-cancer activity and its preparation and use
EP1709969A1 (en) * 2005-04-07 2006-10-11 Praktijkonderzoek Plant en Omgeving B.V. Health promoting dairy and food products containing mushroom glucan produced through fermentation of Grifola frondosa
WO2006119774A1 (en) * 2005-05-13 2006-11-16 Medimush As Feed or food products comprising fungal material
EP1896601A1 (en) * 2005-06-15 2008-03-12 Medimush A/S Bioactive agents produced by submerged cultivation of a basidiomycete cell
US9072776B2 (en) 2005-06-15 2015-07-07 Glycanova As Anti-cancer combination treatment and kit-of-parts
CN100500860C (en) * 2006-07-21 2009-06-17 华南理工大学 High activity golden mushroom polysaccharide-peptide-Fe chelate and its preparation
WO2008097482A2 (en) * 2007-02-05 2008-08-14 Holliday John C Mycellated grain and other myceliated agricultural materials to be used as animal food supplement
RU2475529C2 (en) * 2011-03-14 2013-02-20 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") INHIBITOR OF INFLUENZA A VIRUS REPRODUCTION BASE ON EXTRACT OF BASIDIAL FUNGUS Phallus impudicus
US10729714B2 (en) 2013-02-11 2020-08-04 Glycanova As Basidiomycete-derived cream for treatment of skin diseases
WO2019148418A1 (en) * 2018-02-01 2019-08-08 江南大学 Method for increasing yield of extracellular polysaccharides of edible and medicinal fungus by adding phenylalanine
CN110713550B (en) * 2018-07-12 2022-03-15 浙江省亚热带作物研究所 Method for preparing refined polysaccharide with antibacterial activity by using cordyceps culture
CN113832045A (en) * 2020-06-23 2021-12-24 点斗基因科技(南京)有限公司 Time-sharing fermentation culture method for various plant extracts and various probiotics
WO2021260198A1 (en) * 2020-06-26 2021-12-30 Nutreco Ip Assets B.V. Agaricus blazei fermented grains against lawsonia intracellularis infection
CN112023038B (en) * 2020-09-13 2023-05-26 天津市泌尿外科研究所 Composite immunopotentiator
CN116064699A (en) * 2023-01-19 2023-05-05 安徽师范大学 Application of oyster mushroom extracellular polysaccharide in preparation of medicine for removing algae toxin toxicity

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4174388A (en) * 1977-02-14 1979-11-13 Merck & Co., Inc. Method for preparing hepatitis B immune globulin
US4247541A (en) * 1978-05-12 1981-01-27 Kirin Brewery Company Limited Ks-2-b
US4617379A (en) * 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
US4769363A (en) * 1984-03-08 1988-09-06 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Beta-glucan
US5744187A (en) * 1996-12-16 1998-04-28 Gaynor; Mitchel L. Nutritional powder composition
US6046323A (en) * 1997-07-29 2000-04-04 The Collaborative Group, Ltd. Conformations of PPG-glucan
US6440448B1 (en) * 1998-03-16 2002-08-27 Joseph Intelisano Food supplement/herbal composition for health enhancement
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987166A (en) * 1970-05-13 1976-10-19 Kaken Kagaku Kabushiki Kaisha Treatment of tumors with glucan compositions in mice and rats
US3943247A (en) * 1972-05-22 1976-03-09 Kaken Kagaku Kabushiki Kaisha Treatment of bacterial infections with glucan compositions
JPS5616765B2 (en) * 1975-02-05 1981-04-18
JPS5653101A (en) 1979-09-21 1981-05-12 Kirin Brewery Co Ltd Polysaccharide ks-2-d and its preparation
US4454289A (en) * 1981-03-06 1984-06-12 Takara Shuzo Co., Ltd. Polysaccharides having anticarcinogenic activity and method for producing same
JPS58118519A (en) * 1981-12-29 1983-07-14 Noda Shiyokukin Kogyo Kk Anticancer agent
SU1244179A1 (en) 1983-12-29 1986-07-15 Московский ордена Ленина и ордена Трудового Красного Знамени химико-технологический институт им.Д.И.Менделеева Method of deep-seated cultivation of pleurotis ostreatus (fr) kummer umbf-1300 fungus
EP0292601A1 (en) * 1987-05-14 1988-11-30 Noda Shokukin Kogyo Co., Ltd. Anti aids drug extracted from lentinus edodes
JPS63296662A (en) 1987-05-28 1988-12-02 Toru Arai Food or drink containing mushroom fungus
DE3851386T2 (en) 1987-07-07 1995-03-30 Ajinomoto Kk Use of glycans as antiviral compounds.
JP2676375B2 (en) 1987-08-05 1997-11-12 イハラケミカル工業株式会社 How to grow mushrooms
FR2631829B1 (en) * 1988-05-30 1992-04-03 Pasteur Institut FUNGAL EXOPOLYSACCHARIDES HAVING IMMUNOSTIMULANT ACTIVITY, PROCESS FOR OBTAINING SAME AND THERAPEUTIC COMPOSITION CONTAINING THEM
US4962094A (en) * 1988-10-28 1990-10-09 Alpha Beta Technology, Inc. Glucan dietary additives
JP2947560B2 (en) 1988-11-14 1999-09-13 野田食菌工業株式会社 AIDS treatment and method for producing the same
JPH037236A (en) 1989-02-10 1991-01-14 Nippon Chem Res Kk Agent for inhibiting absorption of herpes virus
US5283239A (en) * 1989-02-10 1994-02-01 Jcr Pharmaceuticals Co. Ltd. Inhibitor of herpesvirus absorption
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
CA2066172A1 (en) * 1989-09-08 1991-03-09 Alpha Beta Technology, Inc. Method for producing soluble glucans
AU647751B2 (en) * 1989-09-08 1994-03-31 Alpha-Beta Technology, Inc. Method for immune system activation
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
US6143731A (en) * 1989-10-20 2000-11-07 The Collaborative Group, Ltd. Glucan dietary additives
US6020324A (en) * 1989-10-20 2000-02-01 The Collaborative Group, Ltd. Glucan dietary additives
DK0500739T3 (en) 1989-11-03 1997-04-14 Alexander S Sun Herbal Treatment of Malignancy
US5223491A (en) * 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
JPH0665649B2 (en) * 1991-02-01 1994-08-24 台糖株式会社 Crustacean biological defense enhancer, infectious disease preventive vaccine and feed
JP3522772B2 (en) * 1991-05-21 2004-04-26 台糖株式会社 Vaccine immunopotentiator
CN1032428C (en) 1992-08-15 1996-07-31 樊菊芬 Technology for extracting Xianggu mushroom saccharide and Xianggu mushroom fungus saccharide
US5519009A (en) * 1993-10-01 1996-05-21 Donzis; Byron A. Solubilized yeast glucan
JP3017630B2 (en) 1993-12-17 2000-03-13 長岡 均 HIV-type virus activity inhibitor
US5554746A (en) * 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US6110892A (en) * 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
JP3404142B2 (en) 1994-09-06 2003-05-06 株式会社日立製作所 Paper attitude control device
US5934012A (en) 1994-11-23 1999-08-10 Hps Biotechnologies, Inc. Process for production of mushroom inoculum
US5576015A (en) * 1995-03-02 1996-11-19 Donzis; Byron A. Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
JP3651697B2 (en) * 1995-03-24 2005-05-25 株式会社アミノアップ化学 New polysaccharide substances
US6117850A (en) * 1995-08-28 2000-09-12 The Collaborative Group, Ltd. Mobilization of peripheral blood precursor cells by β(1,3)-glucan
TW358121B (en) * 1995-12-25 1999-05-11 Hitoshi Nagaoka Method for extracting useful substance from culture medium containing mycelium
US6110692A (en) * 1996-05-01 2000-08-29 The Collaborative Group, Ltd. Receptor for underivatized aqueous soluble β(1-3)-glucan
US6090938A (en) * 1996-05-01 2000-07-18 Collaborative Group, Ltd. Activation of signal transduction by underivatized, aqueous soluble . .beta(1-3)-Glucan
US6084092A (en) * 1997-01-31 2000-07-04 The Collaborative Group, Ltd. β(1-3)-glucan diagnostic assays
US5822940A (en) * 1996-07-17 1998-10-20 Carlin; Steven Composite wall panel
US6413715B2 (en) * 1997-01-31 2002-07-02 The Collaborative Group β(1-3)-glucan diagnostic assays
US5997875A (en) 1998-03-27 1999-12-07 Zhou; James H. Herbal composition and treatment methods
US6369216B1 (en) * 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
AU6261999A (en) * 1998-09-25 2000-04-17 Collaborative Group, Ltd., The Very high molecular weight beta-glucans
JP2000157203A (en) 1998-11-27 2000-06-13 Kobayashi Pharmaceut Co Ltd Enhancer for immunological activity of gamma delta t cell containing extract from mycelium of lentinus edodes sing.
US6919081B1 (en) 1998-11-27 2005-07-19 Kobayashi Pharmaceutical Co., Ltd. Lak activity potentiator orginating in shitake mushroom hyphae extract and lak activity potentiating preparations containing the same
AU2905199A (en) 1999-03-15 2000-10-04 Trustees Of The University Of Pennsylvania, The Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
WO2000065029A1 (en) 1999-04-23 2000-11-02 Tsukuba Biosystem, Ltd. Method for culturing a basidiomycetous fungus in a liquid culture medium
JP4123641B2 (en) 1999-06-18 2008-07-23 ソニー株式会社 Information processing apparatus and method
US6372462B2 (en) 1999-10-15 2002-04-16 Medmyco Ltd. Process for producing, methods and compositions of cholesterol lowering agents from higher basidiomycetes mushrooms
US6383799B1 (en) * 1999-10-15 2002-05-07 Medmyco Ltd. Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom
EP1247529B1 (en) 2000-01-12 2005-12-07 Life Science Laboratories Co., LTD. Physiologically active substance eem-s originating in mushrooms, process for producing the same and drugs
FR2805465B1 (en) 2000-02-28 2003-02-21 Medecine Information Formation NEW PHARMACEUTICAL OR DIETETIC COMPOSITIONS BASED ON MUSHROOMS
CN1143866C (en) 2000-03-20 2004-03-31 武汉迪普生物技术有限公司 Process for separating and purifying lentinan
EP1277472A4 (en) 2000-04-28 2005-06-08 Orient Cancer Therapy Co Ltd Remedies for cancer
EP1155623A1 (en) 2000-05-18 2001-11-21 N.V. Seghers Nutrition Sciences S.A. Growth promoter for animals
JP2002017389A (en) * 2000-06-30 2002-01-22 Mbiotec Co Ltd Method for producing mushroom exopolysaccharide
CN1126547C (en) 2000-07-19 2003-11-05 南京振中生物工程有限公司 Freeze dried lentinan holoside powder injecta and its preparation
JP4647067B2 (en) 2000-08-18 2011-03-09 株式会社アミノアップ化学 Composition derived from basidiomycete culture and use thereof
JP2002191354A (en) 2000-10-06 2002-07-09 Kabaiotekku Co Ltd Method for producing mushroom mycelium
CN1236048C (en) 2000-12-08 2006-01-11 曹文伟 Production process of fungus powder and fungus polysaccharide for food and medicine
WO2002087603A1 (en) 2001-04-27 2002-11-07 Ajinomoto Co., Inc. Immunopotentiators
US6582723B2 (en) * 2001-05-03 2003-06-24 Wayne F. Gorsek Cancer immune composition for prevention and treatment of individuals
JP4238726B2 (en) * 2001-06-01 2009-03-18 味の素株式会社 Drugs for bowel disease
EP1393738A4 (en) 2001-06-01 2004-11-17 Ajinomoto Kk Drugs for diabetes
NO20014256D0 (en) * 2001-09-03 2001-09-03 Bjoern Kristiansen Preparation of immunostimulatory compound
EP1314359A1 (en) 2001-11-21 2003-05-28 N.V. Seghers Nutrition Sciences Growth promoter composition for animals
BE1014638A6 (en) * 2002-02-12 2004-02-03 Univ Liege Method of preparation of derivatives of cell wall from biomass.
PL370866A1 (en) 2002-03-26 2005-05-30 Banyu Pharmaceutical Co, Ltd. Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination
US6702545B2 (en) * 2002-05-01 2004-03-09 Sanford Davis Scholten Venturi fan
KR100470734B1 (en) 2002-06-19 2005-02-21 주식회사 티지 바이오텍 Method for preparation of exo-polymers from submerged mycelial culture of Ganoderma lucidum TG(KCTC 10241BP) and the use thereof
EP1545208A4 (en) * 2002-08-13 2006-04-12 Biopolymer Engineering Inc Methods of using beta glucan as a radioprotective agent
CN1204148C (en) 2002-08-22 2005-06-01 武汉东保科技开发有限责任公司 Separation and purification process of lentinan
US6830310B2 (en) * 2002-10-23 2004-12-14 Hewlett-Packard Development Company, L.P. Detectable markers in cationic polymeric fixers
WO2004075907A2 (en) 2003-02-27 2004-09-10 Ernst-Moritz-Arndt-Universität Greifswald Salutary compositions consisting of fungi containing lipids and thiocyanates
JP4648641B2 (en) 2003-03-20 2011-03-09 日本製粉株式会社 Method for extracting lipid from moss, food and cosmetics
WO2004093518A2 (en) * 2003-04-16 2004-11-04 The University Of Mississippi Immunostimulatory agents in botanicals
CA2527756C (en) 2003-05-15 2014-05-06 Japan Science And Technology Agency Immunostimulating agents
CN1220496C (en) 2003-08-21 2005-09-28 武汉同药药业有限公司 Bougie for treating virus hepatitis and preparing method thereof
CN1528335A (en) 2003-09-27 2004-09-15 南昌弘益科技有限公司 Shii-take fungus polysaccharide drop pill and preparing method thereof
US20050158258A1 (en) * 2004-01-21 2005-07-21 Mary Kay Inc. Methods and compositions for the treatment of skin changes associated with aging and environmental damage
DE102004006825A1 (en) * 2004-02-11 2005-09-01 Maxens Gmbh Process for the preparation of aroma-active terpenes
DK1736206T3 (en) * 2004-02-16 2012-01-16 Tadashi Goino Physiologically active composition and process for its preparation
US7484790B2 (en) * 2004-04-16 2009-02-03 Wheatley Donald G Covering structure having automatic coupling system
US20050238654A1 (en) * 2004-04-26 2005-10-27 Yoshinori Takeda Compositions and methods for weight loss
CA2574060C (en) 2004-07-16 2019-06-25 Medimush A/S Immune modulating compounds from fungi
JP2006241130A (en) 2005-03-01 2006-09-14 Buhei Kono Function of ameliorating collagen fiber formation and wrinkle and flabbiness of human body skin to enhance lifting effect through using polymer component of water-soluble polysaccharide in bracket fungus of the genus fomes
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
CN100453559C (en) 2005-11-04 2009-01-21 杨勇杰 Method for separating lentinan
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
WO2007146440A2 (en) * 2006-06-15 2007-12-21 Biopolymer Engineering, Inc. Dba Biothera, Inc. Glucan preparations
US20080063650A1 (en) * 2006-09-01 2008-03-13 Jun Yan mCRP antagonists and their uses
US20080167268A1 (en) * 2006-09-01 2008-07-10 Jun Yan Particulate beta-glucan compositions for regulating dendritic cells
US20080160043A1 (en) 2007-07-16 2008-07-03 Kim Moo-Sung Preparation method of beta-glucan from schizophyllum commune and composition for external application comprising the same
US7947283B2 (en) 2007-08-30 2011-05-24 Wyntek Corporation Compositions and methods for treating psoriasis by Ganoderma lucidum (Reishi) polysaccharides
KR101097342B1 (en) 2010-03-09 2011-12-23 삼성모바일디스플레이주식회사 Quantum dot organic light emitting device and method of formation thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4174388A (en) * 1977-02-14 1979-11-13 Merck & Co., Inc. Method for preparing hepatitis B immune globulin
US4247541A (en) * 1978-05-12 1981-01-27 Kirin Brewery Company Limited Ks-2-b
US4617379A (en) * 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
US4769363A (en) * 1984-03-08 1988-09-06 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Beta-glucan
US5744187A (en) * 1996-12-16 1998-04-28 Gaynor; Mitchel L. Nutritional powder composition
US6046323A (en) * 1997-07-29 2000-04-04 The Collaborative Group, Ltd. Conformations of PPG-glucan
US6440448B1 (en) * 1998-03-16 2002-08-27 Joseph Intelisano Food supplement/herbal composition for health enhancement
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100021426A1 (en) * 2003-10-03 2010-01-28 Wang ya-chun Methods for making and compositions comprising fermentation products of cordyceps sinensis
US8722056B2 (en) 2003-10-03 2014-05-13 Tcm Biotech International Corp. Methods for making and compositions comprising fermentation products of cordyceps sinensis

Also Published As

Publication number Publication date
WO2003020944A2 (en) 2003-03-13
AU2002328099A1 (en) 2003-03-18
EP1451336B1 (en) 2019-05-15
US20110045026A1 (en) 2011-02-24
EP1451336A2 (en) 2004-09-01
US20050163800A1 (en) 2005-07-28
WO2003020944A3 (en) 2004-06-03
US9249438B2 (en) 2016-02-02
US10471135B2 (en) 2019-11-12
US20140186900A1 (en) 2014-07-03
NO20014256D0 (en) 2001-09-03
WO2003020944A8 (en) 2005-02-17
US20160144008A1 (en) 2016-05-26
US8758768B2 (en) 2014-06-24

Similar Documents

Publication Publication Date Title
US10471135B2 (en) Production of fungal extracellular immune stimulating compounds
US7514085B2 (en) Immune modulating compounds from fungi
US6383799B1 (en) Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom
Hu et al. Isolation and purification of polysaccharides with anti-tumor activity from Pholiota adiposa (Batsch) P. Kumm.(higher Basidiomycetes)
Sułkowska-Ziaja et al. Biologically active compounds of fungal origin displaying antitumor activity
ES2241219T3 (en) NEW IMMUNO STIMULANT POLISACARIDE FROM THE PHELLINUS SPECIES, AND ITS USE.
EP1002541B1 (en) Oral drugs for amelioration of aids symptoms
WO2004099428A1 (en) Extraction method of beta glucan from phellinus linteus through cell destruction and enzyme fermentation method
US20040106187A1 (en) Composition for the culturing of Phellinus linteus mycelium
KR100936176B1 (en) A crude exopolysaccharides produced from Leatiporus sulphureus var. miniatus having hypoglycemic activity and preparation method of the same
EP0491114B1 (en) A process for preparing new non-covalent polysaccharide-protein associations having pharmacological activity
JP2004091780A (en) Polysaccharides of antrodiacamphorata fungus
Adebayo-Tayo et al. Influence of different nutrient sources on exopolysaccharide production and biomass yield by submerged culture of Trametes versicolor and Coprinus sp.
KR100706132B1 (en) Composition for the culturing of Phellinus linteus mycelium
EP0067000B1 (en) Production of a nitrogen-containing polysaccharide having antitumour activity
US6197571B1 (en) Protein polysaccharide 0041
JPS58318B2 (en) Method for producing anticancer substances
KR101735433B1 (en) Culture method for increasing the amount of basidiomycete mycelium and polysaccharide
JP4422404B2 (en) Infection prevention / treatment agent and food
JP4010519B2 (en) Orally administered drug for AIDS treatment
CN113303419A (en) Preparation process of medicinal and edible fungus mixed fermentation mycelium powder
El-Zaher et al. THE ROLE OF EXOPOLYSACCHARIDE PRODUCED BY Pleurotus Sapidus AS MEDICAL AGENT
KR100497751B1 (en) Agrobacterium sp. beta 82 KCTC 10099BP producing water-soluble polysaccharide, water-soluble polysaccharide and producing method thereof
KR20210040237A (en) Culturing conditions of Monascus mycelial for making immuno-stimulating glycan production
KR20050054696A (en) Basidiomycetes-fermented cereal effective in adjusting blood sugar level

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION